


| business Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab PR Newswire Asia |
|
INCHEON, South Korea and NEW YORK Nov. 2, 2020 /PRNewswire/ -- Samsung Biologics Co., Ltd. ("Samsung Biologics") (KRX: 207940.KS) and Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), today announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.
Posted: 2020-11-02 14:56:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.